J&J files Ceftobiprole in Switzerland
A Johnson & Johnson unit has filed for Swiss approval to sell ceftobiprole, marketed in partnership with developer Basilea Pharmaceutical, as a treatment for diabetic foot infections. The drug already is on the Swiss fast track for possible treatment of skin and soft-tissue infections, and it's under review by regulators in the U.S., Canada, and the E.U.
- see this announcement
- read the AFX report
Related Articles:
J&J makes big cuts at Alza and Scios. Report
&J restructures pharma unit, laying off workers. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
